Shots: AstraZeneca will invest $2B in Summit through convertible preferred shares, representing a conversion price of $18.36/share, while the companies will collaborate on the development of ivonescimab & sonesitatug vedotin (sone-ve). The clinical collaboration will evaluate ivonescimab with sone-ve in GI cancers, with studies expected to begin soon. Companies will share study costs, while each…